|
|
|
| home > pmps > autumn 2003 > new orbital welding documentation method improves accuracy for inspections and leads to lower cost per weld |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Orbital tube welding is the recommended method of fabrication for bioprocessing equipment. It has not changed significantly since the 1960s when it was introduced into the aerospace industry. Operators still use the gas tungsten arc welding (GTAW) process and orbit or rotate an electrode around a fixtured weld joint with a predetermined set of weld parameters programmed into the power supply (1). While the orbital welding process itself has remained largely unchanged, advancements in welding system technology have greatly improved weld documentation. For example, today's orbital welding equipment utilises microprocessor technology that provides interface capabilities, enabling data to be transferred to other computers for analysing and customising reports that document quality, cost of welds and other critical information. These types of advancements address increasing requirements for bioprocessing systems.
Weld documentation provides full traceability for all materials and procedures used for construction and maintenance of bioprocessing systems. Such documentation must provide the necessary verification that each weld meets the weld acceptance criteria as defined by the weld specification. In the event of a problem with a system, such as contamination, the documentation provides a means to go back and review each welded connection as part of the effort to track down and find the source.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round
Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing
single cell analysis systems underpinned by its patented picodroplet
technology, announced today that it has closed an additional tranche of
investment of $2.9 million (£2.2 million), securing a total of $4.8
million (£3.7 million) in investment. The funding will be used as
working capital for the Company’s Cyto-Mine® Single Cell Analysis
System, expansion of the UK facility and enable the doubling of
personnel through the opening of a new US Sales Office and Demo Lab in
California.
More info >> |
|
 |
White Papers |
 |
|
Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research
BioFortis
Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive. However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >> |
|
 |
Industry Events |
 |
FlyPharma Europe
22-23 October 2019, Copenhagen, Denmark
The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and
businesses that are ready to uncover the potential in their pharma supply chain. The
event offers an interactive platform to discuss current and future challenges within
pharma and cargo, with topics including market trends, cold chain innovations, latest
regulatory demands, security technology, and how to encourage collaboration between
supply chain players.
There will be plenty of networking opportunities, including a complimentary evening
networking event, where delegates can meet and catch up with senior and executive
pharma
and cargo professionals – gaining strong, new industry contacts and building on
existing ones.
More info >> |
|
|
